Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study by María-Victoria.

Presentación del tema: "Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study by María-Victoria."— Transcripción de la presentación:

1 Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study by María-Victoria Mateos, José-M. Hernández, Miguel-T. Hernández, Norma-C. Gutiérrez, Luis Palomera, Marta Fuertes, Joaquín Díaz-Mediavilla, Juan-J. Lahuerta, Javier de la Rubia, María-José Terol, Ana Sureda, Joan Bargay, Paz Ribas, Felipe de Arriba, Adrian Alegre, Albert Oriol, Dolores Carrera, José García-Laraña, Ramón García-Sanz, Joan Bladé, Felipe Prósper, Gemma Mateo, Dixie-Lee Esseltine, Helgi van de Velde, and Jesús-F. San Miguel Blood Volume 108(7): October 1, 2006 ©2006 by American Society of Hematology

2 The VMP schedule was based on the standard bortezomib monotherapy dosing schedule.
The VMP schedule was based on the standard bortezomib monotherapy dosing schedule. The treatment consisted of 4 6-week cycles followed by the maintenance phase consisting of 5 5-week cycles, giving a total of 49 weeks of treatment. María-Victoria Mateos et al. Blood 2006;108: ©2006 by American Society of Hematology

3 Response to VMP was rapid.
Response to VMP was rapid. The percentage of responding patients achieving their best response to VMP is shown (A) by treatment cycle and (B) over time. María-Victoria Mateos et al. Blood 2006;108: ©2006 by American Society of Hematology

4 Time to events data in patients receiving VMP
Time to events data in patients receiving VMP. (A) PFS, (B) EFS, and (C) OS of patients receiving VMP versus MP historical controls. Time to events data in patients receiving VMP. (A) PFS, (B) EFS, and (C) OS of patients receiving VMP versus MP historical controls. The 16-month time point has been highlighted because it represents the median follow-up in patients treated with VMP. María-Victoria Mateos et al. Blood 2006;108: ©2006 by American Society of Hematology

5 Influence of cytogenetic abnormalities on PFS and EFS
Influence of cytogenetic abnormalities on PFS and EFS. The graphs demonstrate the effect of (A) retinoblastoma gene deletion (Rb del) and (B) IgH translocations (IgH tr) on PFS and EFS. NS indicates not significant (P > .05). Influence of cytogenetic abnormalities on PFS and EFS. The graphs demonstrate the effect of (A) retinoblastoma gene deletion (Rb del) and (B) IgH translocations (IgH tr) on PFS and EFS. NS indicates not significant (P > .05). María-Victoria Mateos et al. Blood 2006;108: ©2006 by American Society of Hematology